China has announced a new five-year plan that sets a concrete target: at least 25% of the world's first-in-class drugs should originate from the country. This is a notable shift from its historical role as a fast-follower in pharmaceuticals, signaling an intent to lead in early-stage innovation.
The plan is part of a wider industrial strategy to strengthen China's biotech ecosystem, from basic research to clinical translation. While the source does not detail specific policy levers, the goal itself implies heavy investment in R&D infrastructure, talent, and regulatory reform.
No other sources were provided, so there is no independent assessment of feasibility or comparison with current shares. The announcement alone, however, marks a clear ambition that could reshape global competition in drug discovery over the next half-decade.